Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae announces major expansion of its test menu for neurological, pediatric, and rare genetic conditions and introduces new panels for inherited metabolic disorders and newborn screening confirmation

Invitae announces major expansion of its test menu for neurological, pediatric, and rare genetic conditions and introduces new panels for inherited metabolic disorders and newborn screening confirmation

March 29, 2016

Company achieves mid-year goal of more than 1,000 genes in production

Hosting an investor call today at 4:30 p.m. ET 

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and expanded panels for neurology, pediatrics, and rare diseases. Invitae also has introduced an entirely new clinical testing area designed to complement newborn screening for metabolic and immunological conditions.

With this expanded test menu, Invitae will ...

Read more


New data on rare diseases demonstrate impact of delayed diagnosis and obstacles for patients and clinicians, including lack of information, time to diagnosis, and accessibility due to cost

New data on rare diseases demonstrate impact of delayed diagnosis and obstacles for patients and clinicians, including lack of information, time to diagnosis, and accessibility due to cost

March 10, 2016

Data honored and presented at the 2016 ACMG Annual Clinical Genetics Meeting

Invitae Corporation (NYSE: NVTA), a genetic information company, today presented data showing that both patients and clinicians in the rare disease community face significant obstacles navigating the diagnosis of rare disease. The poster titled “Rare Disease Diagnosis Obstacles: Patient Perspectives and Physician Findings” has been acknowledged by the American College of Medical Genetics and Genomics (ACMG) as a top poster presented at their Annual Clinical Genetics Meeting ...

Read more


Invitae presents new data demonstrating high concordance of variant classifications for BRCA1/2 across major clinical testing laboratories

Invitae presents new data demonstrating high concordance of variant classifications for BRCA1/2 across major clinical testing laboratories

March 10, 2016

Platform talk given at 2016 ACMG Annual Clinical Genetics Meeting 

Invitae Corporation (NYSE: NVTA), a genetic information company, today presented an important study at the 2016 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, demonstrating that variant classifications in BRCA1 and BRCA2 are highly concordant across major clinical testing laboratories.

In 2015, The New England Journal of Medicine published a report from the ClinGen consortium describing efforts to gather clinically observed genetic variants into ...

Read more


Invitae to present a dozen posters and presentations at the 2016 American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae to present a dozen posters and presentations at the 2016 American College of Medical Genetics Annual Clinical Genetics Meeting

February 25, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it will be presenting a dozen posters and presentations at the 2016 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Tampa, Florida.

The titles and schedule of the Invitae posters and presentations are as follows:

Short Course: Tuesday, March 8, 12:50 p.m. Eastern

  • How to use OMIM: Let me count the ways | Presented by Dr. Robert Nussbaum, Invitae

Platform Talks & Poster Presentations: Thursday, March ...

Read more


Invitae to present at the Cowen and Company 36th Annual Health Care Conference

Invitae to present at the Cowen and Company 36th Annual Health Care Conference

February 23, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that members of the company’s management team will present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at approximately 4:40 p.m. Eastern / 1:40 p.m. Pacific in Boston, Massachusetts.

The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available shortly after the ...

Read more


Invitae announces full year 2015 financial results and 2016 business objectives

Invitae announces full year 2015 financial results and 2016 business objectives

February 09, 2016

Met volume guidance in 2015 with approximately 19,000 billable tests demonstrating more than 400% year-over-year growth, reduced cost of goods sold in Q4 to under $700 per sample, delivered annual revenue of $8.4 million 

Planning to deliver 50,000-70,000 billable tests and expand menu to approximately 3,000 genes by the end of 2016 

Hosting conference call at 4:45 pm ET / 1:45 pm PT 

Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the fourth quarter and full year ...

Read more


Invitae to announce fourth quarter and year-end 2015 financial results and host conference call on February 9, 2016

Invitae to announce fourth quarter and year-end 2015 financial results and host conference call on February 9, 2016

January 26, 2016

Management to present at Leerink Partners 5th Annual Global Healthcare Conference on February 11, 2016 

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its fourth quarter and year-end 2015 financial results on Tuesday, February 9, 2016, and Invitae’s management team will host a conference call that day at 4:45 p.m. Eastern / 1:45 p.m. Pacific to discuss the financial results and recent developments.

The dial-in numbers for the conference call are (866) 393-4306 ...

Read more


Invitae announces it met volume guidance by delivering nearly 19,000 billable tests in 2015 and sets volume guidance at 50,000-70,000 billable tests for 2016

Invitae announces it met volume guidance by delivering nearly 19,000 billable tests in 2015 and sets volume guidance at 50,000-70,000 billable tests for 2016

January 08, 2016

Demonstrated scalability of business with more than 400% year-over-year growth

Planning to expand menu to more than 3,000 genes by the end of 2016

Management to present at the 34th Annual JP Morgan Healthcare Conference

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it met its volume guidance of 17,000-19,000 billable tests delivered in 2015, delivering nearly 19,000 billable tests for the year, representing a greater than 400% increase from the more than 3,600 billable tests delivered ...

Read more